Bridgepoint Group (LON:BPT) Announces Quarterly Earnings Results

Key Points

• Bridgepoint reported 2025 results that beat expectations, with AUM up ~24–25% to $94.1bn, management fees +13% (ex-catch up) and an underlying EBITDA margin of 53%.
• Fundraising momentum remains strong — the firm has raised €14bn toward a €24bn target, with robust demand for flagship funds including ECP VI (≈$3.7bn to date) and BE VIII (IC‑approved >€5.4bn), supporting future fee growth.
• The Calpine exit delivered $4.5bn cash plus 50m Constellation shares, materially derisking near‑term performance fee guidance (expected 20%–25% of income for 2026–27), though half the shares are locked until June 2026 and the rest until June 2027, leaving timing risk.

Bridgepoint Group (LON:BPT - Get Free Report) announced its quarterly earnings results on Thursday. The company reported GBX 26.50 earnings per share for the quarter, Digital Look Earnings reports. Bridgepoint Group had a return on equity of 5.96% and a net margin of 10.35%.

Here are the key takeaways from Bridgepoint Group's conference call:

• Bridgepoint reported 2025 results that beat market expectations with AUM up ~24–25% (to $94.1bn), management fees +13% (ex-catch up), and underlying EBITDA margin at 53%, signalling stronger-than-expected operational performance.
• Fundraising momentum is strong — €14bn raised toward a €24bn target (management remains confident of hitting the target) with robust interest in flagship funds including ECP VI (raised $3.7bn to date) and BE VIII (IC-approved €5.4bn+), supporting fee growth and future deployment.
• The Calpine exit materially derisks near-term performance fee (PRE) guidance and fuels cash generation — Bridgepoint received $4.5bn cash plus 50m Constellation shares, underpinning PRE guidance of 20%–25% of income for 2026–27 despite lock-up timing.
• Strategic diversification is progressing — Bridgepoint added a seasoned 14-person secondaries team (Newbury) and launched the Bridgepoint Generations wealth product, expanding distribution channels and product mix beyond flagship private equity and infrastructure funds.
• Execution and timing risks remain — PRE recognition, final cash receipts and AUM will depend on the timing and pricing of Constellation share sales (50% locked until June 2026, 50% until June 2027), and fundraising/exit timing remains exposed to macro and geopolitical uncertainty.

Bridgepoint Group Stock Up 2.4%

LON BPT traded up GBX 5.40 on Thursday, hitting GBX 232.40. 4,735,438 shares of the stock traded hands, compared to its average volume of 5,596,000. The stock has a 50-day moving average of GBX 267.58 and a 200 day moving average of GBX 289.53. Bridgepoint Group has a twelve month low of GBX 220.80 and a twelve month high of GBX 366.80. The company has a market capitalization of £2.04 billion, a P/E ratio of 43.85, a price-to-earnings-growth ratio of 0.61 and a beta of 1.43. The company has a current ratio of 6.82, a quick ratio of 3.60 and a debt-to-equity ratio of 294.67.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. raised their target price on Bridgepoint Group from GBX 395 to GBX 415 and gave the company a "buy" rating in a research note on Monday, January 5th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Bridgepoint Group currently has an average rating of "Moderate Buy" and a consensus target price of GBX 385.

Bridgepoint Group Company Profile

Bridgepoint Group plc is a private equity and private credit firm specializing in middle market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.